Total
0
Shares
Source: Datametrex AI.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app
  • Medi-Call is a comprehensive mobile application that allows Canadians to visit a doctor through their smartphones
  • Once fully released, the Medi-Call app will be available for free in both the Apple App Store and the Google Play store
  • Datametrex AI is a technology focused company with exposure to AI and machine learning
  • Datametrex AI Ltd. (DM) opened trading at $0.17 per share

Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app.

Medi-Call is a comprehensive mobile application that allows Canadians to visit a doctor through their smartphones.

The closed beta test will be previewed in a webinar on October 28 and selected beta testers will be able to download the app on their mobile devices.

The Medi-Call app is a subscription service that connects patients with doctors via chat and video calls. Following a diagnosis, prescriptions can be provided as needed and sent to the patient’s designated pharmacy.

The app provides accessible healthcare to people who live in rural or isolated communities and make services more readily available and convenient for people with limited time, mobility, or transportation choices.

Marshall Gunter, CEO of Datametrex, commented,

“Medi-Call app is leveraging advanced technology to help bring accessible, affordable healthcare services to patients with doctors supporting Canadians to take greater ownership of their health and wellness outcomes outside of doctor offices and emergency rooms leading to improved health.”

He added, “Dr. Omar Sharif and his team at Medi-Call worked closely with the developers to provide another entry point to healthcare and consultation, which improves the patient’s experience.”

Once fully released, the Medi-Call app will be available for free in both the Apple App Store and the Google Play store.

Datametrex AI is a technology-focused company with exposure to AI and machine learning through its wholly-owned subsidiary, Nexalogy.

The company’s mission is to provide tools that support companies in fulfilling their operational goals, including health and safety, with predictive and preventive technologies.

Datametrex AI Ltd. (DM) opened trading at $0.17 per share.

More From The Market Herald
The Market Herald Video

" Railtown AI Technologies (CSE:RAIL) announces CSE listing

Railtown AI Technologies (RAIL)  has completed its prospectus offering and listing on the Canadian Stock Exchange.
BioMark Diagnostics - Founder and CEO, Rashid Bux

" BioMark (CSE:BUX) to collaborate with AstraZeneca and Pfizer Canada to improve early detection of lung cancer

BioMark Diagnostics (BUX) will participate in a research project that aims to enhance the efficiency of lung cancer screening programs.

" DGTL Holdings (TSXV:DGTL) updates concurrent financing in Engagement Labs acquisition

DGTL Holdings (DGTL) has agreed to amend some of the conditions of its agreement with Engagement Labs.
Plurilock - CEO, Ian Paterson.

" Plurilock (TSXV:PLUR) announces fall 2021 product release

Plurilock Security (PLUR) has announced the availability of its fall 2021 product release.